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1. Introduction
Nowadays, significant part of active pharmaceutical
ingredients (APIs) belongs to Class II of the Bio-
pharmaceutical Classification System [1], that means
these drugs possess low solubility and high perme-
ability. By increasing the dissolution rate and extent
of these drugs their inadequate bioavailability can be
enhanced [2]. Polymers of high water solubility can
form amorphous solid dispersions (ASDs) with such
drugs improving their dissolution characteristics
because there is no need of energy to break the crys-
tal lattice structure [3]. Further advantages, such as
reduced particle size, improved wettability and high-
er porosity, are also characteristic to ASDs [4]. That
is why, this kind of formulation is getting to play a
more and more important role in the pharmaceutical
developments [5]. Among several melting, solvent
and solvent-melting methods published for preparing
ASDs [6], electrospinning (ES) capable of producing
fibrous structures of large surface area seems to be
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especially favourable in the field of pharmaceutical
application [7–18].
Although the electrospinning (ES) is fast developing
with appearance of tri-axial, coaxial, side-by-side
and their combination processes [19–22] the most
common and facile ES equipment is the single nee-
dle apparatus [23, 24]. The single needle electrospin-
ning (SNES) applies a syringe filled with a polymer-
drug containing solution, which is then forced through
a nozzle attached to high voltage. However, the pro-
ductivity of SNES does not satisfy the pharmaceuti-
cal requirements thus scaling-up of the technology
is essential. In recent years, many methods have
been created for this purpose such as needleless elec-
trospinning [25–28], multineedle electrospinning
[29], alternating current electrospinning [30–32],
and high-speed electrospinning (HSES) [33]. The
latter one, where electrostatic and centrifugal forces
are combined, may be a highly suitable technology
in the pharmaceutical industry for mass production
of fibrous drug delivery systems.
The inherently continuous nature of ES can be con-
sidered as a great advantage. This advantage should
even be enhanced by coupling the production of fi-
bres with continuous downstream processing. HSES
device coupled with continuous fibre collection
might be utilized as a part of a continuous processing
line. It is a well-known fact that continuous manu-
facturing is superior to batch processing owing to its
cost effectiveness, robustness, better product quality
control, and so on. Furthermore, continuous manufac-
turing meets the requirements of environmental pro-
tection and it can be more economical than a batch
processing [34, 35]. ES can perfectly fit into this per-
spective. However, there are some cornerstones, such
as continuous collection, grinding and feeding of the
fibres, which cannot be neglected if continuous
downstream processing is desired to be applied.
Utilization of the potential advantages of continuous
technologies requires real-time process monitoring.
Thus the pharmaceutical industry is increasingly fo-
cusing on process analytical technologies (PAT),
which means basically, a large number of analytical
tools, such as Raman, near infrared (NIR) or UV spec-
trometers, monitoring the products and processes
[36, 37]. These methods have been applied success-
fully as in-line techniques in many cases. For instance,
NIR spectroscopy proved to be appropriate for ex-
amining the blend uniformity, content uniformity,
and the tablets coating thickness [38, 39]. Utilization
of Raman spectroscopy also seems to be feasible for
real-time monitoring of freeze-drying [40] and even
real-time feedback control of continuous powder
blending [41]. Furthermore, a PAT system can be par-
ticularly important and useful when tablets include
ASDs since these metastable systems tend to crys-
tallize during processing [42–44]. Raman and NIR
spectroscopies can allow the detection of crystalline
traces in the ASDs [45, 46], thus these analytical
methods can be of enormous significance for in-line
process monitoring [47].
Our goal with this work was to achieve scaled-up
production of spironolactone (SPIR) containing elec-
trospun ASD after optimization of polymers matrices
and drug loadings. Fibrous ASD produced on a larg-
er scale were intended to be formed as immediate-
release tablets. It was of interest whether continuous
manufacturing steps such as continuous fibre collec-
tion, grinding, feeding, and tableting can be realized
with the so-obtained electrospun ASD. Ultimately,
the quantity of crystalline API was needed to be de-
tected by Raman and NIR spectroscopy, while these
two techniques were also compared. As the best
knowledge of the authors, preparation of electrospun
ASDs containing tablets by investigation of contin-
uous process steps has never realized before. The
whole investigation was intended to serve as a basis
of continuous downstream processing of fibrous
ASDs to prepare immediate-release tablets.
2. Experimental
2.1. Materials
Spironolactone (SPIR) with a molar weight of
417 g/mol, a melting point of 205–220°C and a water
solubility of 28 mg/L [48] was kindly provided by
Gedeon Richter Plc. (Budapest, Hungary). PVPVA64
(Kollidon® VA64) obtained from BASF (Ludwigs -
hafen, Germany) is a vinylpyrrolidone-vinylacetate
amorphous copolymer (6:4) with a molecular weight
in the range of 45–70 kDa. Hydroxypropyl methyl-
cellulose (HPMC) 2910 5 mPa·s was supplied by
Aqualon, Hercules (Zwijndrecht, the Netherlands).
Polyvinylpyrrolidone K30 (PVPK30, Plasdone® K30)
was provided by Ashland Inc. (Schaffhausen, Switzer-
land). Microcrystalline cellulose (MCC, Vivapur®
200) was purchased from JRS Pharma (Rosenberg,
Germany). Lactose (Tablettose® 80) was supplied by
Meggle Pharma (Wasserburg, Germany). Croscarmel-
lose sodium (Ac-Di-Sol® SD-711) was a kind gift
from FMC BioPolymer (Brussels, Belgium). All other
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excipients and solvents were analytical grade and
used without further purification.
2.2. Single-needle electrospinning (SNES)
The electrostatic spinneret (with an inner diameter
of 0.5 mm) applied for the experiments were con-
nected with an NT-35 high voltage DC supply
(MA2000; Unitronik Ltd, Nagykanizsa, Hungary).
The electrical potential applied on the spinneret elec-
trode was adjusted during the experiments to 35 kV.
A grounded aluminium plate covered with alumini-
um foil was used as collector. The distance of the spin-
neret and the collector was set to 15 cm. The exper-
iments were performed at room temperature (25°C)
and at 45±5% relative humidity. Polymer solutions
were dosed by a SEP-10S Plus type syringe pump
(Aitecs, Vilnius, Lithuania). Preparation of ASDs with
spironolactone and various polymers was accom-
plished by SNES. The dosing rate was 6 mL/h.
2.3. High speed electrospinning (HSES) and
collection, milling and feeding of the fibres
The scaled-up electrospinning experiments were per-
formed using a high speed electrostatic spinning
setup (Quick2000 Ltd, Tiszavasvári, Hungary) con-
sisting of a round-shaped, stainless steel spinneret
connected to a high speed motor [33]. The polymer
solution was fed with a peristaltic pump with a flow
rate of 200 mL/h. The rotational speed of the spin-
neret was fixed at 15000 rpm, and the voltage ap-
plied on it was 40 kV during the experiments. The
grounded collector covered with aluminium foil was
placed 30 cm from the spinneret in all cases. The ex-
periments were performed at ambient temperature
(25°C) and at 45±5% relative humidity.
To insert ES into continuous manufacturing lines,
collection and forwarding of the fibres to the milling
equipment, and then the grinding step itself have to
be solved. A piece of equipment designed and built
by the authors for continuous collection is described
in Section 3.2.4. The electrospun material was pushed
through a sieve with hole size of 0.8 mm to make it
suitable for blending with excipients. This kind of
milling corresponds to oscillatory or conical milling
that can be utilized in continuous manufacturing.
The ability to feed the material into hoppers is also
inevitable. Feeding experiments were performed on
a DDW-MD0-MT type, twin-screw loss-in-weight
feeder (Brabender Technologie (Duisburg, Germany).
The diameter of the screws was 12 mm.
2.4. Differential scanning calorimetry (DSC)
DSC measurements were performed by a Setaram
DSC 92 (Calure, France) apparatus (sample weight:
~10–15 mg, open pan, nitrogen flush, 50 mL/min,
1.6 bar). The temperature program consisted of an
isothermal part of 1 min at ambient temperature and
subsequent linear heating from 25 to 250°C with a
rate of 10°C/min.
2.5. Thermogravimetric analysis (TGA)
Thermogravimetric examination of the selected com-
position was accomplished by a Q5000 TGA instru-
ment (TA Instruments, USA). The sample was heated
up from 25 to 300°C by 10°C/min. The applied ni-
trogen flush was 50 mL/min during the measurement.
2.6. X-ray powder diffraction (XRPD)
X-ray powder diffraction patterns were docketed
with a PANalytical X’pert Pro MDP X-ray diffrac-
tometer (Almelo, The Netherlands) using Cu-Ka ra-
diation (1.506 Å) and Ni filter. The applied voltage
was 40 kV, while the current was 30 mA. The untreat-
ed materials and the fibrous samples were analysed
between 2θ angles of 4 and 44°.
2.7. Scanning electron microscopy (SEM)
Morphology of the samples was examined by a
JEOL 6380LVa (JEOL, Tokyo, Japan) type scanning
electron microscope in high vacuum. Samples were
fixed by conductive double-sided carbon adhesive
tape and sputtered by gold using ion sputter (JEOL
1200, JEOL, Tokyo, Japan). Applied accelerating volt-
age was set between 5 and 15 kV and working dis-
tance was 10 mm.
2.8. In vitro dissolution measurement
Dissolution studies were performed on a Pharmatest
PTWS 600 dissolution tester (Pharma Test Apparate-
bau AG, Hainburg, Germany). In case of the pure
ASDs the basket method (United States Pharma-
copoeia I) was used, while the tablets were examined
by paddle method (United States Pharmacopoeia II).
Samples equivalent to 50 mg of spironolactone were
weighed without any pre-treatment into the dissolu-
tion baskets and immersed in 900 mL of 0.1 N HCl
dissolution medium kept at a constant temperature
of (37±0.5) °C and stirred at 100 rpm. An on-line
coupled Agilent 8453 UV–Vis spectrophotometer
(Hewlett-Packard, Palo Alto, USA) was used to meas-
ure the concentration of dissolved spironolactone at
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a wavelength of 243 nm. Based on a preliminarily
built calibration (from 1 to 50 mg/L), the concentra-
tion of the dissolved SPIR could be readily calculat-
ed during the measurement. All of the dissolution
measurements were accomplished triplicates in case
of each composition and sample.
2.9. Measurement of the drug solubility
The amount of the dissolved drug was determined
by using UV-Vis spectroscopy. 8.3 mg polymer and
11.1 mg SPIR were weighed in a 100 mL flask filled
up subsequently with the acidic (pH = 1) medium.
The weight of the drug and the polymer was calcu-
lated proportionally based on the dissolution meas-
urements where 125 mg 40% SPIR containing ES
product was applied in 900 mL dissolution medium.
The solutions were stirred for 2 days on a magnetic
stirrer. Before the UV-Vis measurement, the solutions
were filtered through a 0.45 μm filter. Calculation of
the concentration was performed similarly to the in
vitro dissolution test.
2.10. Powder characterization and tableting
Bulk and tapped densities of powder mixture for
tableting were examined on an ERWEKA SVM12
(Heusenstamm, Germany) type tapped density tester.
Hausner ratio can be calculated based on Equa-
tion (1) [49] and Carr index [50] may be determined
according to the Equation (2):
(1)
(2)
The tableting was performed using a Dott Bonapace
CPR6 eccentric tableting machine (Limbiate, Italy)
equipped with 14 mm concave punches. The applied
compression force was about 10 kN. For the disso-
lution measurement, 625 mg tablets were prepared
in which the API was 50 mg (125 mg ASD) and they
also contained 10% disintegrant (Ac-Di-Sol®), 1%
glidant (Aerosil), 1% lubricant (magnesium stearate),
and 34–34% tablet fillers (MCC, lactose). Tablet
breaking force (with 10 tablets) was measured on a
Schleuniger 4M type hardness tester (Thun, Switzer-
land).
2.11. Raman spectroscopy
One of the spectroscopy methods for detection of
crystalline API in blends and tablets was the Raman
spectroscopy. A Kaiser RamanRxn2® Hybrid in situ
analyzer (Kaiser Optical Systems, Ann Arbor, USA)
connected with PhAT (Pharmaceutical Area Testing)
probe was applied to gain the spectra of the samples.
A 400 mW, 785 nm diode laser (Invictus) was uti-
lized for illuminating the products. Reflection mode
was used for measuring calibration samples of pow-
der mixtures and tablets. In addition, the device was
also operated in transmission mode in case of tablets.
The diameter of the laser spot size was extended to
6 mm and the nominal focus length was 250 mm.
The examined spectral range was between 200 and
1890 cm–1. During the measurements the resolution
was 4 cm–1, which provided 1690 variables during
data processing. In case of reflection mode, an ac-
quisition time of 30 seconds gave adequate Raman
intensity and signal-to-noise ratio. In transmission
mode, acquisition time of 2 minutes was adjusted due
to 4 mm thickness of 625 mg tablets to reach similar
quality with the backscattered spectra. 5 spectra per
powder samples were acquired and 2 repeated meas-
urements per tablets (both side of the products) were
satisfactory for calibration.
2.12. NIR spectroscopy
The other applied spectroscopy instrument was a
Fourier-transform Near Infrared (FT-NIR) spectrom-
eter (Bruker MPA NIR, Bruker OPTIK GmbH,
Ettlingen, Germany) in diffuse reflection mode.
Spectra were obtained in the spectral range of 3700–
15000 cm–1 with a resolution of 8 cm–1, and 128 scans
were accumulated. A high intensity NIR light source
(Tungsten) was utilized as excimer, and the PbS de-
tector operated at room temperature. Double Sided
Forward-Backward acquisition mode was used dur-
ing the measurements. Simple glass and tablet sam-
ple holders were used for investigating powder mix-
tures and tablets. Number of the repetitions was the
same as in Raman measurements. However, the ex-
periments were taken place only in reflection mode
because transmission method was not possible due
to the tablet thickness.
2.13. Multivariate calibration of Raman and
NIR spectroscopy
Calibration samples of 2.5 g powder were prepared
for Raman and NIR spectroscopic studies with 0,
0.5, 2, 5, 10, 20, 50 and 100% crystalline spirono-
lactone content followed by preparation of three
tablets of 625 mg at each concentration levels. Both
Hausner ratio
bulk
tapped
t
t
=
Carr idex 100
trapped
tapped bulk$ t
t t
=
-U Z
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Raman and NIR spectroscopy measurements were
evaluated by using MATLAB 8.2. (MathWorks,
USA) program with PLS Toolbox 7.8.2. (Eigenvec-
tor Research, USA). Partial least squares (PLS) re-
gression method was applied for the determination
of the crystalline API content. During PLS model-
ling coordinate transformation was performed on
the original n×λ sized dataset (where n is the num-
ber of spectra used for the calibration and λ is the
number of variables, i.e. wavenumbers). The creat-
ed new variables (latent variables, LVs) combine
the original variables in the way that the latent vari-
ables are orthogonal to each other, and the first few
variables describe the possible highest covariance
with the dependant variable (in this case the crys-
talline API content). The number of latent variables,
necessary for the model, was determined by mini-
mizing the root mean square error of cross valida-
tion (RMSECV).
The performance of the PLS model can be further
improved by selecting a subset of spectrum wave -
numbers resulting in the most accurate model. For
this, interval PLS variable selection method was ap-
plied [51], which is a systematic search for the best
combination of variables. The spectra are divided
into variable windows (consecutive variable subsets)
sized depending on user requirement (in this study
50 wavenumbers/windows were used), then several
PLS models are built with systematically adding
(forward mode) or eliminating (reverse mode) vari-
able windows for the calculations. The searching al-
gorithm is running until the model performance (e.g.
RMSECV) cannot be improved by including or ex-
cluding additional variable windows.
All spectra were pre-processed before PLS model-
ling. In the case of Raman spectra, Automatic Whit-
taker Filter baseline correction with asymmetry pa-
rameter p = 0.001 and smoothing parameter λ = 105,
normalization to unit length, and mean centring were
applied. NIR spectra were corrected by Savitzky-
Golay first derivative (15 points/window, second
order smoothing), standard normal variate (SNV),
and mean centring. The models were validated by 6-
fold venetian blind cross-validation leaving out one
sample per concentration levels at each calculation
step. The models were compared by the coefficient
of determination (R2), the root mean square error of
calibration and cross-validation (RMSEC/RM-
SECV) and by the limit of detection (LoD) and limit
of quantification (LoQ).
3. Results and discussion
SPIR containing ASDs were prepared by SNES and
HSES for enhancing the drug dissolution. Three dif-
ferent polymers (HPMC, PVPK30 and PVPVA64)
and three different drug loadings (20, 30, and 40%)
were screened by SNES. The best composition was
chosen based on the in vitro dissolution tests. Scaled-
up production of this composition was performed
using HSES. Furthermore, parts of a possible con-
tinuous line (collection, grinding, feeding) were test-
ed as well. Eventually, the effect of crystalline API
content on the dissolution of tablets containing elec-
trospun ASD was investigated. Raman and NIR
spectroscopy was applied for detection of crystalline
and amorphous forms of SPIR and the performance
of these two methods were compared. 
3.1. Screening study by SNES
Limited data is available on the electrospun SPIR
containing ASDs. As a consequence, a screening
study with three polymers and optimization of poly-
mer-drug concentration was to be done at first. Table 1
presents the different polymer-drug combinations in-
vestigated.
HPMC requires the application of DCM, and only
small concentration of it can be achieved in the so-
lution. However, with the vinylpyrrolidone-based
polymers (PVPK30 and PVPVA64), more environ-
mentally friendly solvent combinations were at-
tempted to be used. The utilization of IPA is partic-
ularly interesting since this is not a conventional ES
solvent. Nevertheless, the fibre formation was fea-
sible for each composition.
3.1.1. DSC and XRPD results
The amorphicity of the different compositions was
examined by DSC. Based on the thermograms ob-
tained (Figure 1a), it can be concluded that the melt-
ing peak of the drug (~211°C) did not appear for the
electrospun products. This indicates that spironolac-
tone was amorphous in all these compositions. Ap-
pearance of peaks between 65 and 94.4°C can be ex-
plained by the presence of water absorbed by the
ASD. Peaks between 222 and 240°C indicate the de-
composition of SPIR. Interestingly, HPMC mitigate
this decomposition as a significantly smaller peak
appears in the resulted thermograms. Total amorphi-
sation is also supported by results of XRPD: the
sharp peaks of crystalline SPIR did not appear with
any of the different fibrous samples (Figure 1b).
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3.1.2. Selection of the optimal composition
based on the dissolution
According to the dissolution results (Table 1), the well
water-soluble PVPVA64 provided the best dissolu-
tion profile since nearly 80% of SPIR was released
in the first 5 minutes from the PVPVA64_SPIR40%
sample. Slower dissolutions and lower extents were
observed with HPMC systems (less than 30% drug
dissolved in 5 minutes). PVPK30 gave the least
favourable result: approximately only two times more
drug was released at 90 minutes than in the case of
the crystalline drug. The amount of the SPIR mole-
cules dissolved from the crystalline sample into the
medium was 17.5% at 90 minutes.
Not only the higher dissolution, but the extent of su-
persaturation is of great interest since it can deter-
mine the diffusion performance of the drug through
membranes [52]. The solubility of SPIR, both in
pure form and mixed with polymers, was determined
in 0.1 N HCl by UV-Vis spectroscopy after 2 days
of stirring at room temperature. Three repeated
measurements were performed in all cases. It can be
established that polymers increase the solubility of
crystalline SPIR slightly, but there is no significant
difference between them (Figure 2).
High polymer content of the tablet can, however,
generate disadvantageous tablet properties such as
slow disintegration. Therefore, the polymer content
should be reduced as much as possible. Based on
these considerations and on the obtained results the
ASD of PVPVA64 and 40% SPIR seemed to be the
most suitable for further experiments.
3.1.3. Investigation of the fibres with SEM
The selected composition was investigated by SEM
to get information on the sample morphology. Elec-
trospinning is well-known for its capability of pro-
ducing nanofibres with enhanced surface area with
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Table 1. Various composition of electrospun solutions and dissolution results of the ES products. Applied dissolution method:
900 mL 0.1 M HCl dissolution medium, 37±0.5 °C, 100 rpm, basket method, 50 mg API content. (DCM:
dichloromethane; EtOH: ethanol; ACE: acetone; IPA: isopropyl alcohol; bold: chosen composition for scale-up).
Samples
Polymer
[mg]
Spironolactone
[mg]
Applied Solvents
[8 mL]
Dissolved drug at 5 and 90 min
[%]
HPMC_SPIR20% 0600 0150 DCM+EtOH (1:1) 28.0 83.8
HPMC_SPIR30% 0600 0257 DCM+EtOH (1:1) 28.4 81.4
HPMC_SPIR40% 0600 0400 DCM+EtOH (1:1) 22.1 67.9
PVPK30_SPIR20% 2000 0500 ACE+EtOH (1:1) 08.9 50.8
PVPK30_SPIR30% 2000 0857 ACE+EtOH (1:1) 11.1 48.3
PVPK30_SPIR40% 2000 1333 ACE+EtOH (1:1) 16.3 49.2
PVPVA64_SPIR20% 2100 0525 IPA+ACE (2:1) 41.1 68.5
PVPVA64_SPIR30% 2100 0900 IPA+ACE (2:1) 74.2 79.7
PVPVA64_SPIR40% 2100 1400 IPA+ACE (2:1) 78.9 87.9
cryst. SPIR n/a n/a n/a 04.7 17.5
Figure 1. Results of DSC (a) and XRPD (b) experiments.
which instantaneous release can be achieved [9, 10,
53]. Fibres with diameter in the nano range could be
produced with PVPK30 and HPMC polymers (data
not shown). With IPA, a solvent with relatively large
viscosity (2.86 cP at 15°C), slightly thicker PVPVA64-
based fibres with some beads could be obtained (Fig-
ure 3a). An increase in viscosity usually leads to
thicker fibres [54, 55]. However, it can occur that fi-
bres with larger diameter release the encapsulated
drug faster than nanofibres due to the easier accessi-
bility [56]. Based on the SEM images, it can be stated
that the majority of the fibres prepared by SNES pos-
sesses a diameter below 5 µm (4.26±2.08 μm), there-
fore their specific surface is fairly large. As it is
shown hereinafter, the dissolution rate was not im-
paired, fast release could be achieved. Another in-
teresting fact is the fragmentation of the fibres which
can cause by PVPVA64. For this reason, a compar-
ison was made between the SEM images of the fibre
before grinding (Figure 3a) and after grinding (Fig-
ure 3b). It can be seen in Figure 3 that no significant
differences are between the two images. This obser-
vation proves that the fibres are very fragile, which
is advantageous from the downstream processing
(e.g. grinding) point of view.
3.2. Scaling-up of the electrospinning
SNES samples had appropriate dissolution and mor-
phology, but SNES is known to be inappropriate for
mass production of the fibres. The technology of
HSES was used to increase the productivity. The
scaled-up electrospinning technique was applied with
the optimal composition (matrix: PVPVA64, drug
loading: 40%) and more than thirtyfold productivity
was achieved during this production (SNES: ~2.1 g/h;
HSES: ~70 g/h). In consequence, the amount of the
ES material produced by HSES was sufficient for
examining tableting and continuous manufacturing
circumstances.
3.2.1. DSC, XRPD and SEM results of the HSES
sample
Characterization of the product was investigated by
the methods used previously, such as DSC, XRPD and
SEM. Figures 4a, b prove the success of scaling-up:
total amorphisation of SPIR was achieved for this
ASD as well (according to DSC and XRPD results).
The same peak has been appeared in case of HSES
samples in the DSC results than before by the SNES
materials. For this reason, a TGA measurement was
performed with the selected composition (Figure 5).
A significant weight loss from the temperature of
the endothermic peak (~200°C) can be seen in the
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Figure 2. Solubility of different polymer-drug mixtures (n = 3).
Figure 3. Scanning electron microscopic images of the selected composition prepared by SNES before grinding (a) and after
grinding (b) (PVPVA64_SPIR40%).
thermogram which proves the decomposition of the
SPIR. The morphology and the diameter of the
HSES fibres (5.70±3.75 μm), as shown in SEM image
of the milled fibres (Figure 4c), were similar to the
SNES materials. Grinding of the sample, which is an
important step to obtain a blendable powder, is ob-
viously noticeable on the image since appropriately
short fibres could be obtained.
3.2.2. In vitro dissolution of the HSES sample
The dissolution of the HSES product was compared
to that of the same SNES composition. Dissolution
profiles were compared by the ‘difference factor, f1’
and the ‘similarity factor, f2’ [57, 58]. These can be
used in bioequivalence studies to compare the in
vitro dissolutions of different forms. Based on our
calculations (f1 = 0.39%; f2 = 98.14%), the dissolu-
tion characteristics of the HSES fibres were similar
to the SNES materials which is also clearly visible
in Figure 6.
3.2.3. Tableting
The next step was to convert the ASD into an appli-
cable formulation. While the electrospun material
has ‘poor’ flowability (according to the Hausner ratio:
1.36 and Carr index: 26%), which might hinder the
tableting process. Therefore, the addition of flowa-
bility aiding excipients is necessary. Interestingly,
the powder mixture consisting of ASD of SPIR and
PVPVA64 and the tableting excipients had much im-
proved flowability, which is surprising considering
results of similar subject in the literature [59]. (Haus-
ner ratio: 1.12, Carr index: 11%; according to the
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Figure 4. Characterization of the fibrous ASD obtained by
HSES by (a) DSC (b) XRPD and (c) SEM.
Figure 5. Comparison of the DSC and TGA results in case
of the selected composition.
Figure 6. In vitro dissolution of the HSES product (900 mL
0.1 M HCl dissolution medium, 37±0.5°C, 100 rpm,
basket method, 50 mg API content, n = 3).
U.S. Pharmacopeia, powder blends with Hausner ra-
tios between 1.12 and 1.18 and Carr indices between
11 and 15% receive the second best, ‘good’ classifi-
cation for flowability). The bulk density of this blend
was also appropriate for tableting. The breaking force
of the prepared tablets achieved high value between
100 and 134 N (Table 2).
The in vitro dissolution of the tablets was investigat-
ed in order to find out if ASD system retains its ad-
vantageous properties even after tableting. Figure 7
shows a comparison of dissolution profiles of crys-
talline SPIR, scaled-up ASD product, and tablet. Re-
lease of SPIR from the tablets was observed to have
a similar extent and a slightly slower rate compared
to that of the pure ASD.
3.2.4. Insertion of ES into a continuous system
Scaled-up production of drug-loaded fibres and prepa-
ration of appropriate blend and tablets has been
proved to be feasible. One of the main pharmaceutical
trends nowadays is the transfer from batch to con-
tinuous manufacturing. In order to reveal if ES fits
into this perspective and can be inserted into contin-
uous lines, some fundamentals have to be estab-
lished. The possible way to generate tablets from
electrospun ASDs in a continuous manner is depict-
ed in Figure 8. The produced fibres need to be col-
lected and forwarded to a milling equipment (milling
was proven to be feasible earlier) and then to a loss-
in-weight feeder. After gravimetric feeding and ho-
mogenization, the tablets can obviously be produced
in a continuous manner. Investigation of homoge-
nization of fibrous ASD with excipients in a twin-
screw blender and homogeneity is a subject of a dif-
ferent, ongoing study.
3.2.5. Collection and milling of the fibres
To achieve continuous production of electrospun
fibre-based tablets, mechanical engineering devel-
opments are also needed. The first step is the contin-
uous collection of the produced fibres, which is not
solved in the pharmaceutical. For this purpose, we de-
signed a machine made of aluminium with three rolls
(Figure 9a, rolls are marked by 1, 2, and 3). The fibre
collection occurs on a polypropylene (PP) fleece con-
stantly moving on the rolls twirled by an electrical
motor (12 V direct current motor, gear ratio 3000:1).
This fleece is a hot pressed filament, which is strong,
flexible, and thin enough not to have an effect on the
electric field strength. One of the most important pa-
rameters is the distance between the spinneret and
the grounded collector (marked by 4 in Figure 9a).
In our experiment (PVPVA64 fibres), this was cho-
sen to be 300 mm, since this way the evaporation of
the solvent can be complete, and sticking of the sheet
to the fleece can be avoided. At the bottom of the
equipment, a doctor blade made of aluminium peels
the fibrous sheet off the fleece, making it nonwoven
to be suitable for collecting fibres again (Figure 9b).
This way the removed product could be easily for-
warded to the next step, to the milling equipment (e.g.
oscillational mill or conical mill, Figure 8). The
milling of brittle PVPVA64-based fibres is feasible
as it was shown earlier.
3.2.6. Gravimetric feeding of the electrospun ASD
In continuous manufacturing, the precise dosing of
the components with loss-in-weight feeders is nec-
essary to ensure satisfying tablet quality. However, low
bulk density and weak flowability (like the fibrous
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Table 2. Physical properties of the powder mixture and the
tablets.
Properties of the pow-
der mixture
Bulk density 0.499 g/mL
Tapped density 0.561 g/mL
Hausner Ratio 1.12
Carr’s index 11%
Properties of the tablets Compression force 10,72±1,47 kN
Weight 625.9±0.8 mg
Tablet breaking force 122.7±11.9 N
Friability 0.23%
Thickness 3.88±0.033 mm
Figure 7. In vitro dissolution of amorphous spironolactone
containing tablet (900 mL 0.1 M HCl dissolution
medium, 37±0.5 °C, 100 rpm, basket method for
HSES product and paddle method for tablets,
50 mg API content, n = 3).
ASD has) can hinder the appropriate feeding. The
maximum mass rate for the fibrous ASD was 40 g/h
that could be maintained precisely by the twin screw
gravimetric feeder with 12 mm screw diameter. Pre-
sumably, this rate can be easily enhanced by increasing
the size of the feeder and/or the type of the screws.
Another possible method to increase the feeding rate
is the addition of feeding aiding excipients. In this
case, MCC (Vivapur® 200) was added to the fibres
(double amount compared to the ASD), and 385 g/h
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Figure 8. Schematic design of a continuous line from ES to directly compressed tablets with real-time detection of crys-
tallinity. Green rectangles mark the areas investigated in this work.
Figure 9. Equipment for collecting fibres using by three rolls (a) and a blade (b) for peeling the samples.
feeding rate was achieved. This means ~130 g/h for
the electrospun ASD in case of 1:2 ES and MCC ratio,
which is already a quite satisfying value for such a
small system. At this scale 24000 tablets/day might
be manufactured with 50 mg dose of SPIR.
3.3. Spectroscopic investigation of crystalline
spironolactone content
Physical instability of amorphous solid dispersions
during storage may lead to phase separation and
crystallization. Crystalline traces can deteriorate the
generally good dissolution of amorphous drugs
which is a critical point from quality assurance view-
point. In order to investigate the extent of dissolution
reduction caused by crystalline SPIR in the case of
tablets, various blends with different crystalline
SPIR content were compressed into tablets and ex-
posed to dissolution test.
It is discernible, that the more the crystalline SPIR
content the worse the dissolution as it can be seen in
Figure 10. Nonetheless, standard deviations were
found to be really small in all cases. These results
highlight that it is worth examining the crystallinity
of the API during both the production and storage.
3.4. Results of the Raman and NIR
spectroscopy
As the presence of crystalline API can impair the dis-
solution, the fast detection of crystalline SPIR in the
tablets during production by means of Raman and
NIR spectroscopies might be very important for
quality assurance. These techniques are non-destruc-
tive and can be applied without any sample prepara-
tion and in-line mode. Both tablets and powders
were investigated by reflection mode and in the case
of Raman spectroscopy moreover by transmission
mode, too. Several combinations of spectral ranges
and pre-processing methods were tested to obtain the
most accurate regression (PLS) models. Hereinafter,
only the models best fitting to each spectroscopic
method and measuring mode are discussed.
Figure 11 and Figure 12 shows the coefficients of
determination (R2 values), besides the predicted and
measured concentrations for calibration and cross
validation. In addition, limit of detection (LoD) and
limit of quantificatiton (LoQ) values were calculated
and presented in Table 3. In case of Raman models
of powders, crystalline API cannot be detected, under
2.89% (LoD) and exact quantity of SPIR can be cal-
culated over 8.75% (LoQ). If detecting lower crys-
tallinities is still required, a calibration between 0
and 10% is necessary. The NIR spectroscopic model,
compared to Raman results, determine the crys-
talline content of powders with 4.73 and 14.33%
LoD/LoQ values, which are approximately 1.6 times
higher than that of the Raman spectroscopy. Based
on these results, more accurate detection can be
achieved by Raman spectroscopy suggesting that it
is more suitable for in-line analysis of crystallinity.
Furthermore, it was also noticed that the calibration
was more precise using powder samples. This is
proven by the fact that the reflection Raman model
of blends was found to be the most precise one.
Real time detection of crystalline traces by a non-de-
structive analytical technique such as NIR or Raman
spectroscopy is of great importance regarding new
pharmaceutical trend, continuous manufacturing
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Figure 10. Dissolution of crystalline SPIR content tablets
(900 mL 0.1 M HCl dissolution medium,
37±0.5°C, 100 rpm, paddle method, 50 mg API
content, n = 3).
Table 3. Parameters of the models.
Results of NIR spectroscopy Results of Raman spectroscopy
Blends
Tablets
(reflection mode)
Blends
Tablets
(reflection mode)
Tablets
(transmission mode)
RMSEC 1.40 2.23 0.98 1.04 2.16
RMSECV 1.62 4.16 1.19 1.60 2.64
LoQ 14.33 23.77 8.75 10.22 23.60
LoD 4.73 7.84 2.89 3.37 7.79
[60]. A further goal of the future is to enhance the
prediction power of the models and to correlate NIR
and Raman spectra with the dissolution and achieve
real-time release testing.
3.5. Prediction of dissolution profile based on
non-destructive measurement
Dissolution results of the above mentioned calibration
samples were served as the basis of the prediction.
In the first step, dissolution values at 90 minutes were
depicted as a function of the investigated SPIR con-
tents (Figure 13). Based on this graph, a well-fitting
power function relationship can be observed between
the dissolution percentage and the crystalline API
content. Similarly to the Figure 13, power functions
can be fitted on the dissolution percentages versus
crystalline drug content at all the dissolution sam-
pling time points (Table 4). Utilizing these equations
and the spectroscopically measured value of crys-
talline drug content dissolution percentages at the
given time points can be calculated.
In a consequence, the described method seems to be
appropriate to estimate the dissolution profiles of the
tablets based on crystalline drug content determina-
tion using non-destructive spectroscopy (Raman or
NIR) which can be considered as a real-time release
testing method.
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Figure 11. Predicted and measured data of Raman experiments. Reflection mode and transmission mode were used for meas-
uring tablets (b, c). Blends were investigated only in reflection mode (a).
Figure 12. Predicted and measured concentration during NIR measurements in case of blends (a) and tablets (b).
Figure 13. Dissolution values at 90 minutes as a function of
crystalline API content (900 mL 0.1 M HCl dis-
solution medium, 37±0.5 °C, 100 rpm, paddle
method, 50 mg API content).
4. Conclusions
In the present work, SPIR containing electrospun
amorphous solid dispersions with different polymer
matrices and drug loadings were characterized. Ac-
cording to the characterization methods applied
(DSC, XRPD, SEM), all electrospun products were
completely amorphous, and the micro-sized fibres
were beneficial in terms of dissolution enhancement.
PVPVA64 with 40% drug loading was found to be
the most suitable composition for improved dissolu-
tion and scale-up using high speed electrospinning
(HSES). HSES enables practical utilization of ASDs
by preparing fibres more productively, and a contin-
uous production of electrospun fibre-based tablets
seems to be also doable. This latter statement is
based on the feasible continuous collection, grind-
ing, and precise feeding of the fibrous ASD.
Both NIR and Raman spectroscopies are suitable to
detect crystalline SPIR in the prepared fibres and
subsequent tablets. The Raman technique and reflec-
tion mode were found to be superior to NIR and
transmission mode, respectively. Narrow calibration
ranges (for instance, 0–10%) would certainly give
more accurate models, hence real-time process and
quality control could be realized with these non-de-
structive analytical tools.
The obtained results confirm that scaled-up produc-
tion of electrospun ASDs followed by continuous
collection and continuous downstream processing
(grinding, feeding, tableting) coupled with real-time
process analytical technologies (PATs) is feasible.
This way, not only the advantageous quality attrib-
utes of the electrospun ASDs but also the reliability
of PAT controlled continuous production can be re-
alized.
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